126 results on '"Pfarr K"'
Search Results
2. Filariasis and lymphoedema
- Author
-
PFARR, K. M., DEBRAH, A. Y., SPECHT, S., and HOERAUF, A.
- Published
- 2009
- Full Text
- View/download PDF
3. The mitochondrial heat shock protein 60 (HSP60) is up-regulated in Onchocerca volvulus after the depletion of Wolbachia
- Author
-
Pfarr, K. M., Heider, U., Schmetz, C., Büttner, D. W., and Hoerauf, A.
- Published
- 2008
4. Pre-clinical development of the antibiotic Corallopyronin A
- Author
-
Schiefer, A, Krome, A, Kehraus, S, Hübner, M, Hüttel, S, Jansen, R, Pogorevc, D, Schäberle, T, Roth, M, König, GM, Keller, C, Rupp, J, Wagner, K, Müller, R, Stadler, M, Pfarr, K, and Hoerauf, A
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Corallopyronin A (CorA) is a natural product produced by Corallococcuscoralloides that inhibits bacterial DNA-dependent RNA polymerase. Because CorA binds to the switch region and not in the active site, it is active against rifampicin-resistant S. aureus and MRSA. We have shown in vitro and in vivo[for full text, please go to the a.m. URL], Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
- Published
- 2018
- Full Text
- View/download PDF
5. Neglected Diseases: Neue Therapiestrategien bei Filariosen – sind sie der nötige Paradigmenwandel für die Elimination bis 2030?
- Author
-
Klarmann-Schulz, U, Debrah, AY, Batsa-Debrah, L, Pfarr, K, Osei-Mensah, J, Kuepper, JM, Schiefer, A, Specht, S, Huebner, MP, and Hoerauf, A
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Mit der Entdeckung der endosymbiotischen Wolbachien wurde in den späten neunziger Jahren eine neue Zielstruktur gegen Lymphatische Filariose (LF) und Onchozerkose gefunden. Während die zur Massenbehandlung (MDA) eingesetzten Medikamente Ivermectin, Albendazol und Diethylcarbamazin hauptsächlich[zum vollständigen Text gelangen Sie über die oben angegebene URL], Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
- Published
- 2018
- Full Text
- View/download PDF
6. Chemotherapy of filariasis – established strategies and new developments
- Author
-
Specht, S, Debrah, AY, Klarmann, U, Mand, S, Hoerauf, A, and Pfarr, K
- Subjects
ddc: 610 ,parasitic diseases ,lcsh:RC109-216 ,610 Medical sciences ,Medicine ,lcsh:Infectious and parasitic diseases - Abstract
Lymphatic filariasis (lympoedema and hydrocoele) and onchocerciasis (dermatitis and ocular inflammation) caused by the parasitic filarial nematodes Wuchereria bancrofti, Brugia spp. and Onchocerca volvulus lead to severe morbidity in developing tropical countries. Mass drug administration (MDA) programmes use ivermectin or diethylcarbamazine, often combined with albendazole, with the aim to eliminate filarial diseases. However, these drugs primarily only kill the first stage larvae, the microfilariae. Removal of the parasites’ mutualistic endosymbionts of the genus Wolbachia using anti-rickettsial drugs results in permanent worm sterility and death of the adult worms. Since it is currently not compatible with mass drug administration due to the comparatively long treatment time of 4–6 weeks, doxycycline has been recommended for physician-monitored treatment of individuals. For individuals suffering from filarial pathology, the use of doxycycline is the first drug to have the additional advantage of improving lymphoedema. However, new drugs and regimes need to be in the pipeline in order to tackle the upcoming or already existing problem areas, such as those with ivermectin resistance, areas coendemic for loiasis, or end-game scenarios. Here, we summarize current treatment options and review current research approaches for optimization of anti-helminthic therapy, including the exploration of optimized delivery strategies of ivermectin and albendazole, the discovery and development of new antibiotics for anti-wolbachial chemotherapy and macrofilaricidal antihelminthics., GMS Infectious Diseases; 1:Doc03; ISSN 2195-8831
- Published
- 2013
- Full Text
- View/download PDF
7. Der Quotient aus Calprotectin zu Gesamteiweiß im Aszites ermöglicht die Diagnose der spontanen bakteriellen Peritonitis und hat darüber hinaus prognostische Bedeutung
- Author
-
Lutz, P, primary, Pfarr, K, additional, Nischalke, HD, additional, Krämer, B, additional, Göser, F, additional, Nattermann, J, additional, Sauerbruch, T, additional, Hoerauf, A, additional, Strassburg, CP, additional, and Spengler, U, additional
- Published
- 2014
- Full Text
- View/download PDF
8. P485 THE RATIO OF ASCITES CALPROTECTIN TO TOTAL PROTEIN IS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR SPONTANEOUS BACTERIAL PERITONITIS IN LIVER CIRRHOSIS
- Author
-
Lutz, P., primary, Pfarr, K., additional, Nischalke, H.-D., additional, Krämer, B., additional, Goeser, F., additional, Nattermann, J., additional, Sauerbruch, T., additional, Hoerauf, A., additional, Strassburg, C.P., additional, and Spengler, U., additional
- Published
- 2014
- Full Text
- View/download PDF
9. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites
- Author
-
Lutz, PL, primary, Parcina, M, additional, Bekeredjian-Ding, I, additional, Pfarr, K, additional, Nischalke, HD, additional, Nattermann, J, additional, Sauerbruch, T, additional, Hoerauf, A, additional, Strassburg, CP, additional, and Spengler, U, additional
- Published
- 2014
- Full Text
- View/download PDF
10. Musiktheater im Spannungsfeld zwischen Tradition und Experiment (1960 bis 1980)
- Author
-
Mahling, C.-H., Pfarr, K., and Rijksuniversiteit Groningen
- Published
- 2002
11. Das holländische Musiktheater in den Jahren 1960-1980: ein stilistisches 'Labyrinth'
- Author
-
van Reijen, P.W., Mahling, C.-H., Pfarr, K., and Faculteit der Letteren
- Published
- 2002
12. The mitochondrial heat shock protein 60 (HSP60) is up-regulated inOnchocerca volvulusafter the depletion ofWolbachia
- Author
-
PFARR, K. M., primary, HEIDER, U., additional, SCHMETZ, C., additional, BÜTTNER, D. W., additional, and HOERAUF, A., additional
- Published
- 2008
- Full Text
- View/download PDF
13. A Randomized, Double-Blind Clinical Trial of a 3-Week Course of Doxycycline plus Albendazole and Ivermectin for the Treatment of Wuchereria bancrofti Infection
- Author
-
Turner, J. D., primary, Mand, S., additional, Debrah, A. Y., additional, Muehlfeld, J., additional, Pfarr, K., additional, McGarry, H. F., additional, Adjei, O., additional, Taylor, M. J., additional, and Hoerauf, A., additional
- Published
- 2006
- Full Text
- View/download PDF
14. Antibiotics which Target the Wolbachia Endosymbionts of Filarial Parasites: A New Strategy for Control of Filariasis and Amelioration of Pathology
- Author
-
Pfarr, K., primary and Hoerauf, A., additional
- Published
- 2006
- Full Text
- View/download PDF
15. PowerPC AS A10 64-bit RISC microprocessor
- Author
-
Bishop, J. W., primary, Campion, M. J., additional, Jeremiah, T. L., additional, Mercier, S. J., additional, Mohring, E. J., additional, Pfarr, K. P., additional, Rudolph, B. G., additional, Still, G. S., additional, and White, T. S., additional
- Published
- 1996
- Full Text
- View/download PDF
16. Wolbachia Endosymbionts: An Achilles' Heel of Filarial Nematodes.
- Author
-
Hoerauf, A. and Pfarr, K.
- Published
- 2007
- Full Text
- View/download PDF
17. It Takes Two: Lessons From the First Nematode Wolbachia Genome Sequence.
- Author
-
Pfarr, K., Foster, J., and Slatko, B.
- Published
- 2007
- Full Text
- View/download PDF
18. The Effect of Disturbed Turbulence Structure on the Preston-Tube Method of Measuring Wall Shear Stress
- Author
-
Kiske, S., primary, Ram, V. Vasanta, additional, and Pfarr, K., additional
- Published
- 1982
- Full Text
- View/download PDF
19. The Effect of Disturbed Turbulence Structure on the Preston-Tube Method of Measuring Wall Shear Stress
- Author
-
Kiske, S., primary, Ram, V. Vasanta, additional, and Pfarr, K., additional
- Published
- 1981
- Full Text
- View/download PDF
20. Retarded Onchocerca volvulus L1 to L3 larval development in the Simulium damnosum vector after anti-wolbachial treatment of the human host
- Author
-
Albers Anna, Esum Mathias, Tendongfor Nicholas, Enyong Peter, Klarmann Ute, Wanji Samuel, Hoerauf Achim, and Pfarr Kenneth
- Subjects
Onchocerca volvulus ,Wolbachia ,doxycycline ,development ,onchocerciasis ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The human parasite Onchocerca volvulus harbours Wolbachia endosymbionts essential for worm embryogenesis, larval development and adult survival. In this study, the development of Wolbachia-depleted microfilariae (first stage larvae) to infective third stage larvae (L3) in the insect vector Simulium damnosum was analysed. Methods Infected volunteers in Cameroon were randomly and blindly allocated into doxycycline (200 mg/day for 6 weeks) or placebo treatment groups. After treatment, blackflies were allowed to take a blood meal on the volunteers, captured and dissected for larval counting and DNA extraction for quantitative real-time PCR analysis. Results PCR results showed a clear reduction in Wolbachia DNA after doxycycline treatment in microfilariae from human skin biopsies with > 50% reduction at one month post-treatment, eventually reaching a reduction of > 80%. Larval stages recovered from the insect vector had similar levels of reduction of endosymbiotic bacteria. Larval recoveries were analysed longitudinally after treatment to follow the kinetics of larval development. Beginning at three months post-treatment, significantly fewer L3 were seen in the blackflies that had fed on doxycycline treated volunteers. Concomitant with this, the proportion of second stage larvae (L2) was significantly increased in this group. Conclusions Doxycycline treatment and the resulting decline of Wolbachia endobacteria from the microfilaria resulted in retarded development of larvae in the insect vector. Thus, anti-wolbachial treatment could have an additive effect for interrupting transmission by reducing the number of L3 that can be transmitted by blackflies.
- Published
- 2012
- Full Text
- View/download PDF
21. No resistance development against corallopyronin A in Wolbachia in C6/36 cell culture.
- Author
-
Behrmann LV, Lämmer C, Schiefer A, Neufeld H, Grosse M, Stadler M, Bierbaum G, Hoerauf A, and Pfarr K
- Published
- 2024
- Full Text
- View/download PDF
22. Adherence to Hygiene Protocols and Doxycycline Therapy in Ameliorating Lymphatic Filariasis Morbidity in an Endemic Area Post-Interruption of Disease Transmission in Ghana.
- Author
-
Debrah LB, Klarmann-Schulz U, Osei-Mensah J, Kuehlwein JM, Mubarik Y, Nadal J, Ayisi-Boateng NK, Ricchiuto A, Opoku VS, Sullivan SM, Mensah DA, Horton J, Rahamani AA, Budge PJ, Gbedema S, Korir PJ, Opoku J, Pfarr K, Kontoh DB, Kellings A, Gyasi C, Obeng MA, Gruetzmacher B, Fordjour FA, Kroidl I, Horn S, Kuutiero EK, Wauschkuhn C, Ngenya A, Mackenzie C, Wanji S, Kalinga A, Ottesen EA, Hoerauf A, and Debrah AY
- Subjects
- Humans, Ghana epidemiology, Male, Female, Adult, Middle Aged, Double-Blind Method, Hygiene, Endemic Diseases prevention & control, Young Adult, Filaricides therapeutic use, Filaricides administration & dosage, Patient Compliance, Adolescent, Doxycycline therapeutic use, Doxycycline administration & dosage, Elephantiasis, Filarial drug therapy, Elephantiasis, Filarial prevention & control, Elephantiasis, Filarial epidemiology, Elephantiasis, Filarial transmission
- Abstract
Filarial lymphedema (LE) remains a significant global problem despite the progress made toward elimination of lymphatic filariasis (LF). In Ghana, the main approach to LF is preventive chemotherapy, but this has minimal impact on individuals who have already developed LE. In 2018-2020, a 24-month randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy of stringent hygiene measures using the Essential Package of Care with or without additional administration of doxycycline (DOX) to improve filarial leg LE. This study enrolled 356 participants with LE stages 1-3 from two districts in the Upper East Region of Ghana. In addition to regular training on appropriate care for their affected legs, participants were randomized to receive 6 weeks of either 200 mg/day DOX (n = 117), 100 mg/day DOX (n = 120), or matching placebo (n = 119). Participants were seen every 2 months, with clinical measurements done at 6, 12, 18, and 24 months to assess the status of affected legs. There was a trend toward later appearance of acute attacks after DOX, but surprisingly, DOX showed no effect on LE stage progression. In all groups, leg LE improvement was more common (DOX 200 mg: n = 23 [20%]; DOX 100 mg: n = 23 [19.5%]; placebo: n = 32 [27.4%]) than LE worsening (DOX 200 mg: n = 2 [1.7%]; DOX 100 mg: n = 3 [2.5%]; placebo: n = 2 [1.7%]). Overall, these data show a strong benefit from adherence to a strict hygiene protocol, with some added potential benefit for DOX in preventing acute attacks.
- Published
- 2024
- Full Text
- View/download PDF
23. The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis.
- Author
-
Risch F, Kazakov A, Specht S, Pfarr K, Fischer PU, Hoerauf A, and Hübner MP
- Subjects
- Humans, Animals, Filaricides therapeutic use, Drug Discovery trends, Elephantiasis, Filarial drug therapy, Elephantiasis, Filarial prevention & control, Onchocerciasis drug therapy, Onchocerciasis prevention & control
- Abstract
Although lymphatic filariasis and onchocerciasis have been targeted for global elimination, these helminth infections are still a major public health problem across the tropics and subtropics. Despite decades of research, treatment options remain limited and drugs that completely clear the infections, and can be used on a large scale, are still unavailable. In the present review we discuss the strengths and weaknesses of currently available treatments and new ones in development. Novel candidates (corallopyronin A, DNDi-6166, emodepside, and oxfendazole) are currently moving through (pre)clinical development, while the development of two candidates (AWZ1066S and ABBV-4083/flubentylosin) was recently halted. The preclinical R&D pipeline for filarial infections continues to be limited, and recent setbacks highlight the importance of continuous drug discovery and testing., Competing Interests: Declaration of interests A.H., K.P., and S.S. hold three patents for corallopyronin A to treat human and animal filarial infections (US 9168244 B2, US 9687470 B2, and EP 2704708 B1). M.P.H., K.P., and A.H. have applied for a patent concerning solid and liquisolid formulations of corallopyronin A (application US20230181522A1). M.H. and A.H. are members of the section antiparasitic therapy of the Paul Ehrlich Gesellschaft für Infektionstherapie and board members of the German Society for Tropical Medicine Travel Medicine and Global Health (DTG). M.H. is also a board member of the German Society of Parasitology (DGP). All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Erratum for Balthazar et al., "A laboratory-based predictive pathway for the development of Neisseria gonorrhoea e high-level resistance to corallopyronin A, an inhibitor of bacterial RNA polymerase".
- Author
-
Balthazar JT, Golparian D, Unemo M, Read TD, Grosse M, Stadler M, Pfarr K, Schiefer A, Hoerauf A, Edwards JL, Vassylyev DG, and Shafer WM
- Published
- 2024
- Full Text
- View/download PDF
25. In vitro extracellular replication of Wolbachia endobacteria.
- Author
-
Behrmann LV, Meier K, Vollmer J, Chiedu CC, Schiefer A, Hoerauf A, and Pfarr K
- Abstract
Obligate intracellular endobacteria of the genus Wolbachia are widespread in arthropods and several filarial nematodes. Control programs for vector-borne diseases (dengue, Zika, malaria) and anti-filarial therapy with antibiotics are based on this important endosymbiont. Investigating Wolbachia , however, is impeded by the need for host cells. In this study, the requirements for Wolbachia w AlbB growth in a host cell-free in vitro culture system were characterized via qPCRs. A cell lysate fraction from Aedes albopictus C6/36 insect cells containing cell membranes and medium with fetal bovine serum were identified as requisite for cell-free replication of Wolbachia . Supplementation with the membrane fraction of insect cell lysate increased extracellular Wolbachia replication by 4.2-fold. Replication rates in the insect cell-free culture were lower compared to Wolbachia grown inside insect cells. However, the endobacteria were able to replicate for up to 12 days and to infect uninfected C6/36 cells. Cell-free Wolbachia treated with the lipid II biosynthesis inhibitor fosfomycin had an enlarged phenotype, seen previously for intracellular Wolbachia in C6/36 cells, indicating that the bacteria were unable to divide. In conclusion, we have developed a cell-free culture system in which Wolbachia replicate for up to 12 days, providing an in vitro tool to elucidate the biology of these endobacteria, e.g., cell division by using compounds that may not enter the C6/36 cells. A better understanding of Wolbachia biology, and in particular host-symbiont interactions, is key to the use of Wolbachia in vector control programs and to future drug development against filarial diseases., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Behrmann, Meier, Vollmer, Chiedu, Schiefer, Hoerauf and Pfarr.)
- Published
- 2024
- Full Text
- View/download PDF
26. A laboratory-based predictive pathway for the development of Neisseria gonorrhoeae high-level resistance to corallopyronin A, an inhibitor of bacterial RNA polymerase.
- Author
-
Balthazar JT, Golparian D, Unemo M, Read TD, Grosse M, Stadler M, Pfarr K, Schiefer A, Hoerauf A, Edwards JL, Vassylyev DG, and Shafer WM
- Subjects
- Humans, Drug Resistance, Bacterial genetics, Mutation, Drug Resistance, Multiple, Bacterial genetics, Biofilms drug effects, Biofilms growth & development, Lactones, Neisseria gonorrhoeae drug effects, Neisseria gonorrhoeae genetics, Neisseria gonorrhoeae enzymology, DNA-Directed RNA Polymerases genetics, DNA-Directed RNA Polymerases metabolism, Anti-Bacterial Agents pharmacology, Microbial Sensitivity Tests, Gonorrhea microbiology, Gonorrhea drug therapy, Bacterial Proteins genetics, Bacterial Proteins metabolism
- Abstract
The continued emergence of Neisseria gonorrhoeae strains that express resistance to multiple antibiotics, including the last drug for empiric monotherapy (ceftriaxone), necessitates the development of new treatment options to cure gonorrheal infections. Toward this goal, we recently reported that corallopyronin A (CorA), which targets the switch region of the β' subunit (RpoC) of bacterial DNA-dependent RNA polymerase (RNAP), has potent anti-gonococcal activity against a panel of multidrug-resistant clinical strains. Moreover, in that study, CorA could eliminate gonococcal infection of primary human epithelial cells and gonococci in a biofilm state. To determine if N. gonorrhoeae could develop high-level resistance to CorA in a single step, we sought to isolate spontaneous mutants expressing any CorA resistance phenotypes. However, no single-step mutants with high-level CorA resistance were isolated. High-level CorA resistance could only be achieved in this study through a multi-step pathway involving over-expression of the MtrCDE drug efflux pump and single amino acid changes in the β and β' subunits (RpoB and RpoC, respectively) of RNAP. Molecular modeling of RpoB and RpoC interacting with CorA was used to deduce how the amino acid changes in RpoB and RpoC could influence gonococcal resistance to CorA. Bioinformatic analyses of whole genome sequences of clinical gonococcal isolates indicated that the CorA resistance determining mutations in RpoB/C, identified herein, are very rare (≤ 0.0029%), suggesting that the proposed pathway for resistance is predictive of how this phenotype could potentially evolve if CorA is used therapeutically to treat gonorrhea in the future., Importance: The continued emergence of multi-antibiotic-resistant strains of Neisseria gonorrhoeae necessitates the development of new antibiotics that are effective against this human pathogen. We previously described that the RNA polymerase-targeting antibiotic corallopyronin A (CorA) has potent activity against a large collection of clinical strains that express different antibiotic resistance phenotypes including when such gonococci are in a biofilm state. Herein, we tested whether a CorA-sensitive gonococcal strain could develop spontaneous resistance. Our finding that CorA resistance could only be achieved by a multi-step process involving over-expression of the MtrCDE efflux pump and single amino acid changes in RpoB and RpoC suggests that such resistance may be difficult for gonococci to evolve if this antibiotic is used in the future to treat gonorrheal infections that are refractory to cure by other antibiotics., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
27. Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial.
- Author
-
Pinazo MJ, Forsyth C, Losada I, Esteban ET, García-Rodríguez M, Villegas ML, Molina I, Crespillo-Andújar C, Gállego M, Ballart C, Ramirez JC, Aden T, Hoerauf A, Pfarr K, Vaillant M, Marques T, Fernandes J, Blum B, Ribeiro I, Sosa-Estani S, Barreira F, and Gascón J
- Subjects
- Adult, Humans, Adolescent, Young Adult, Middle Aged, Treatment Outcome, Nifurtimox adverse effects, Double-Blind Method, Chagas Disease drug therapy, Trypanosoma cruzi, Nitroimidazoles
- Abstract
Background: More than six million people worldwide, particularly in vulnerable communities in Latin America, are infected with Trypanosoma cruzi, the causative agent of Chagas disease. Only a small portion have access to diagnosis and treatment. Both drugs used to treat this chronic, neglected infection, benznidazole and nifurtimox, were developed more than 50 years ago, and adverse drug reactions during treatment pose a major barrier, causing 20% of patients to discontinue therapy. Fexinidazole proved efficacious in an earlier, interrupted clinical trial, but the doses evaluated were not well tolerated. The present study evaluated fexinidazole at lower doses and for shorter treatment durations., Methods: In this randomised, double-blind, phase 2 trial, we included adult patients (18-60 years old) with confirmed T cruzi infection by serology and PCR and without signs of organ involvement. We evaluated three regimens of fexinidazole-600 mg once daily for 10 days (6·0 g total dose), 1200 mg daily for 3 days (3·6 g), and 600 mg daily for 3 days followed by 1200 mg daily for 4 days (6·6 g)-and compared them with a historical placebo control group (n=47). The primary endpoint was sustained negative results by PCR at end of treatment and on each visit up to four months of follow-up. This study is registered with ClinicalTrials.gov, NCT03587766, and EudraCT, 2016-004905-15., Findings: Between Oct 16, 2017, and Aug 7, 2018, we enrolled 45 patients (n=15 for each group), of whom 43 completed the study. Eight (19%) of 43 fexinidazole-treated patients reached the primary endpoint, compared with six (13%) of 46 in the historical control group. Mean parasite load decreased sharply following treatment but rebounded beginning 10 weeks after treatment. Five participants had seven grade 3 adverse events: carpal tunnel, sciatica, device infection, pneumonia, staphylococcal infection, and joint and device dislocation. Two participants discontinued treatment due to adverse events unrelated to fexinidazole., Interpretation: The fexinidazole regimens in this study had an acceptable safety profile but did not prove effective against T cruzi infection. Development of fexinidazole monotherapy for treating T cruzi infection has been stopped., Funding: The Drugs for Neglected Diseases initiative., Competing Interests: Declaration of interests AH reports being Chair of the German Network against Neglected Tropical Diseases, a German advocacy group to fight neglected tropical diseases. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Mesoporous Silica as an Alternative Vehicle to Overcome Solubility Limitations.
- Author
-
Becker T, Heitkötter J, Krome AK, Schiefer A, Pfarr K, Ehrens A, Grosse M, Sandargo B, Stammberger I, Stadler M, Hübner MP, Kehraus S, Hoerauf A, and Wagner KG
- Abstract
Toxicological studies are a part of the drug development process and the preclinical stages, for which suitable vehicles ensuring easy and safe administration are crucial. However, poor aqueous solubility of drugs complicates vehicle screening for oral administration since non-aqueous solvents are often not tolerable. In the case of the anti-infective corallopyronin A, currently undergoing preclinical investigation for filarial nematode and bacterial infections, commonly used vehicles such as polyethylene glycol 200, aqueous solutions combined with cosolvents or solubilizers, or aqueous suspension have failed due to insufficient tolerability, solubility, or the generation of a non-homogeneous suspension. To this end, the aim of the study was to establish an alternative approach which offers suitable tolerability, dissolution, and ease of handling. Thus, a corallopyronin A-mesoporous silica formulation was successfully processed and tested in a seven-day toxicology study focused on Beagle dogs, including a toxicokinetic investigation on day one. Sufficient tolerability was confirmed by the vehicle control group. The vehicle enabled high-dose levels resulting in a low-, middle-, and high-dose of 150, 450, and 750 mg/kg. Overall, it was possible to achieve high plasma concentrations and exposures, leading to a valuable outcome of the toxicology study and establishing mesoporous silica as a valuable contender for challenging drug candidates.
- Published
- 2024
- Full Text
- View/download PDF
29. Culicoides Species of the Rain Forest Belt of the Littoral Region of Cameroon: Their Incrimination in the Transmission of Mansonella perstans .
- Author
-
Ebai R, Kien CA, Fombad FF, Esofi F, Ouam E, Ntuh AN, Amambo GN, Gandjui VNT, Chunda VC, Nietcho F, Nchang LC, Magha C, Cho JF, Esum ME, Enyong PI, Pfarr K, Hoerauf A, Ritter M, and Wanji S
- Abstract
Biting midges belonging to the genus Culicoides are tiny stout-shaped hematophagous insects and are thought to transmit the filarial nematode Mansonella perstans . Little is known about the Culicoides fauna in the rain forest belt of the Littoral Region of Cameroon. This study was designed to investigate the diversity, abundance and distribution of Culicoides spp. and their role as the purported vector(s) of M. perstans . Overnight light trap collections and human landing catches (HLCs) revealed eight species of Culicoides with C. grahamii being the most abundant species followed by C. milnei . Four anthropophilic species ( C. inornatipennis , C. grahamii , C. fulvithorax and C. milnei ) were determined by the HLCs with a higher abundance in the 4-6 p.m. collections. The drop trap technique and Mp419 LAMP assay confirmed C. milnei to be the most efficient vector in enabling the development of the microfilarial stage to the infective larval form of M. perstans . The LAMP assay also revealed that natural transmission of this nematode is fostered by C. milnei and C. grahamii in the wild. In conclusion, C. milnei was shown to be the main vector of M. perstans in the rain forest belt of the Littoral Region of Cameroon.
- Published
- 2024
- Full Text
- View/download PDF
30. First case of Dirofilaria hongkongensis infection in Germany presenting as a breast tumour.
- Author
-
Schroeder J, Rothe C, Hoerauf A, Kroidl I, Pfarr K, and Hübner MP
- Subjects
- Animals, Female, Humans, Dirofilaria, Germany, Aged, Breast Neoplasms, Dirofilariasis diagnosis
- Published
- 2023
- Full Text
- View/download PDF
31. Optimized strategy for real-time qPCR detection of Onchocerca volvulus DNA in pooled Simulium sp. blackfly vectors.
- Author
-
Doherty M, Grant JR, Pilotte N, Bennuru S, Fischer K, Fischer PU, Lustigman S, Nutman TB, Pfarr K, Hoerauf A, Unnasch TR, Hassan HK, Wanji S, Lammie PJ, Ottesen E, Mackenzie C, and Williams SA
- Subjects
- Animals, Humans, DNA, Mitochondrial, Ivermectin therapeutic use, Onchocerca genetics, Intestinal Volvulus, Onchocerca volvulus genetics, Onchocerciasis drug therapy, Simuliidae parasitology
- Abstract
Background: Onchocerca volvulus is a filarial parasite that is a major cause of dermatitis and blindness in endemic regions primarily in sub-Saharan Africa. Widespread efforts to control the disease caused by O. volvulus infection (onchocerciasis) began in 1974 and in recent years, following successful elimination of transmission in much of the Americas, the focus of efforts in Africa has moved from control to the more challenging goal of elimination of transmission in all endemic countries. Mass drug administration (MDA) with ivermectin has reached more than 150 million people and elimination of transmission has been confirmed in four South American countries, with at least two African countries having now stopped MDA as they approach verification of elimination. It is essential that accurate data for active transmission are used to assist in making the critical decision to stop MDA, since missing low levels of transmission and infection can lead to continued spread or recrudescence of the disease., Methodology/principal Findings: Current World Health Organization guidelines for MDA stopping decisions and post-treatment surveillance include screening pools of the Simulium blackfly vector for the presence of O. volvulus larvae using a PCR-ELISA-based molecular technique. In this study, we address the potential of an updated, practical, standardized molecular diagnostic tool with increased sensitivity and species-specificity by comparing several candidate qPCR assays. When paired with heat-stable reagents, a qPCR assay with a mitochondrial DNA target (OvND5) was found to be more sensitive and species-specific than an O150 qPCR, which targets a non-protein coding repetitive DNA sequence. The OvND5 assay detected 19/20 pools of 100 blackfly heads spiked with a single L3, compared to 16/20 for the O150 qPCR assay., Conclusions/significance: Given the improved sensitivity, species-specificity and resistance to PCR inhibitors, we identified OvND5 as the optimal target for field sample detection. All reagents for this assay can be shipped at room temperature with no loss of activity. The qPCR protocol we propose is also simpler, faster, and more cost-effective than the current end-point molecular assays., Competing Interests: The authors have declared that no competing interests exist., (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
- Published
- 2023
- Full Text
- View/download PDF
32. Epilepsy and nodding syndrome in association with an Onchocerca volvulus infection drive distinct immune profile patterns.
- Author
-
Arndts K, Kegele J, Massarani AS, Ritter M, Wagner T, Pfarr K, Lämmer C, Dörmann P, Peisker H, Menche D, Al-Bahra M, Prazeres da Costa C, Schmutzhard E, Matuja W, Hoerauf A, Layland-Heni LE, and Winkler AS
- Subjects
- Animals, Humans, Uganda epidemiology, Cytokines, Onchocerciasis epidemiology, Onchocerca volvulus, Nodding Syndrome epidemiology, Nodding Syndrome etiology, Intestinal Volvulus complications, Epilepsy epidemiology
- Abstract
Previous studies have described the association of onchocerciasis (caused by Onchocerca volvulus) with epilepsy, including nodding syndrome, although a clear etiological link is still missing. Cases are found in different African countries (Tanzania, South Sudan, Uganda, Democratic Republic of the Congo, Central African Republic and Cameroon). In our study we investigated immunological parameters (cytokine, chemokine, immunoglobulin levels) in individuals from the Mahenge area, Tanzania, presenting with either epilepsy or nodding syndrome with or without O. volvulus infection and compared them to O. volvulus negative individuals from the same endemic area lacking neurological disorders. Additionally, cell differentiation was performed using blood smears and systemic levels of neurodegeneration markers, leiomodin-1 and N-acetyltyramine-O, β-glucuronide (NATOG) were determined. Our findings revealed that cytokines, most chemokines and neurodegeneration markers were comparable between both groups presenting with epilepsy or nodding syndrome. However, we observed elevated eosinophil percentages within the O. volvulus positive epilepsy/nodding syndrome patients accompanied with increased eosinophilic cationic protein (ECP) and antigen-specific IgG levels in comparison to those without an O. volvulus infection. Furthermore, highest levels of NATOG were found in O. volvulus positive nodding syndrome patients. These findings highlight that the detection of distinct biomarkers might be useful for a differential diagnosis of epilepsy and nodding syndrome in O. volvulus endemic areas. Trial-registration: NCT03653975., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Arndts et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
33. First genome-wide association study for lymphatic filariasis in a West African population points to a human leukocyte antigen-mediated disease pathophysiology.
- Author
-
Grover S, Opoku VS, Debrah LB, Maj C, Osei-Mensah J, Mensah DA, Hoerauf A, Debrah AY, Schumacher J, and Pfarr K
- Subjects
- Male, Animals, Humans, Genome-Wide Association Study, Wuchereria bancrofti genetics, Ghana epidemiology, HLA Antigens, Elephantiasis, Filarial genetics, Elephantiasis, Filarial epidemiology, Lymphedema
- Abstract
Objectives: Lymphatic filariasis (LF) represents a parasitic disease caused by filarial nematodes. Although some infected individuals present an asymptomatic course, others suffer severe chronic lymphatic pathology, including lymphedema, hydrocele, and elephantiasis. Several studies have shown that host genetic factors influence LF susceptibility and chronic pathology. The current study aimed to conduct the first genome-wide association study to systematically determine LF susceptibility., Methods: We analyzed genome-wide single-nucleotide polymorphism data from 1459 LF cases and 1492 asymptomatic controls of West African (Ghanaian) descent., Results: We identified two independent genome-wide significant associated genetic variants near the genes HLA-DQB2 (rs7742085) and HLA-DQA1 (rs4959107) contributing to LF and/or lymphedema susceptibility (P <5.0 × 10
-8 , odds ratios [ORs] >1.30). We also observed suggestive evidence of LF associations (P <1.0 × 10-6 ) at two non-HLA loci, near the genes ZFHX4-AS1 (rs79562145) and CHP2 (rs12933387). In contrast, we could not replicate any previously reported LF associations drawn from candidate gene association studies. On the polygenic level, we show that our genome-wide association study data explain 24-42% of LF heritability, depending on an assumed population prevalence of 0.5-5.0%., Conclusion: Our findings point to an involvement of HLA-mediated immune mechanisms in LF pathophysiology., Competing Interests: Declarations of Competing Interest The authors have no competing interests to declare., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
34. Reduced Type 2 Innate Lymphocyte Cell Frequencies in Patent Wuchereria bancrofti -Infected Individuals.
- Author
-
Tamadaho RSE, Osei-Mensah J, Arndts K, Debrah LB, Debrah AY, Layland LE, Hoerauf A, Pfarr K, and Ritter M
- Abstract
Approximately 51 million individuals suffer from lymphatic filariasis (LF) caused mainly by the filarial worm Wuchereria bancrofti . Mass drug administration (MDA) programs led to a significant reduction in the number of infected individuals, but the consequences of the treatment and clearance of infection in regard to host immunity remain uncertain. Thus, this study investigates the composition of myeloid-derived suppressor cells (MDSCs), macrophage subsets and innate lymphoid cells (ILCs), in patent (circulating filarial antigen (CFA)+ microfilariae (MF)+) and latent (CFA+MF-) W. bancrofti -infected individuals, previously W. bancrofti -infected (PI) individuals cured of the infection due to MDA, uninfected controls (endemic normal (EN)) and individuals who suffer from lymphoedema (LE) from the Western Region of Ghana. Frequencies of ILC2 were significantly reduced in W. bancrofti -infected individuals, while the frequencies of MDSCs, M2 macrophages, ILC1 and ILC3 were comparable between the cohorts. Importantly, clearance of infection due to MDA restored the ILC2 frequencies, suggesting that ILC2 subsets might migrate to the site of infection within the lymphatic tissue. In general, the immune cell composition in individuals who cured the infection were comparable to the uninfected individuals, showing that filarial-driven changes of the immune responses require an active infection and are not maintained upon the clearance of the infection.
- Published
- 2023
- Full Text
- View/download PDF
35. Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections.
- Author
-
Petralia LMC, van Diepen A, Nguyen DL, Lokker LA, Sartono E, Bennuru S, Nutman TB, Pfarr K, Hoerauf A, Wanji S, Foster JM, and Hokke CH
- Subjects
- Humans, Animals, Antibodies, Helminth, Antigens, Immunoglobulin G, Filariasis, Brugia malayi
- Abstract
Parasitic nematodes responsible for filarial diseases cause chronic disablement in humans worldwide. Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets. While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection. We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals. To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa , Onchocerca volvulus , Mansonella perstans and Wuchereria bancrofti , four closely related filarial nematodes. IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species. In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals. For these infection groups, Brugia malayi , Onchocerca volvulus and Mansonella perstans , we further studied the different IgG subclasses to Brugia malayi glycans. In all three infections, IgG1 and IgG2 appeared to be the major subclasses involved in response to glycan antigens. Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications. Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes. We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response. We believe that our initial findings could be further exploited to develop disease-specific diagnostics as part of an integrated approach for filarial disease control., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Petralia, van Diepen, Nguyen, Lokker, Sartono, Bennuru, Nutman, Pfarr, Hoerauf, Wanji, Foster and Hokke.)
- Published
- 2023
- Full Text
- View/download PDF
36. Filariasis research - from basic research to drug development and novel diagnostics, over a decade of research at the Institute for Medical Microbiology, Immunology and Parasitology, Bonn, Germany.
- Author
-
Karunakaran I, Ritter M, Pfarr K, Klarmann-Schulz U, Debrah AY, Debrah LB, Katawa G, Wanji S, Specht S, Adjobimey T, Hübner MP, and Hoerauf A
- Abstract
Filariae are vector borne parasitic nematodes, endemic in tropical and subtropical regions causing avoidable infections ranging from asymptomatic to stigmatizing and disfiguring disease. The filarial species that are the major focus of our institution's research are Onchocerca volvulus causing onchocerciasis (river blindness), Wuchereria bancrofti and Brugia spp. causing lymphatic filariasis (elephantiasis), Loa loa causing loiasis (African eye worm), and Mansonella spp causing mansonellosis. This paper aims to showcase the contribution of our institution and our collaborating partners to filarial research and covers decades of long research spanning basic research using the Litomosoides sigmodontis animal model to development of drugs and novel diagnostics. Research with the L. sigmodontis model has been extensively useful in elucidating protective immune responses against filariae as well as in identifying the mechanisms of filarial immunomodulation during metabolic, autoimmune and infectious diseases. The institute for Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn (UKB), Bonn, Germany has also been actively involved in translational research in contributing to the identification of new drug targets and pre-clinical drug research with successful and ongoing partnership with sub-Saharan Africa, mainly Ghana (the Kumasi Centre for Collaborative Research (KCCR)), Cameroon (University of Buea (UB)) and Togo (Laboratoire de Microbiologie et de Contrôle de Qualité des Denrées Alimentaires (LAMICODA)), Asia and industry partners. Further, in the direction of developing novel diagnostics that are sensitive, time, and labour saving, we have developed sensitive qPCRs as well as LAMP assays and are currently working on artificial intelligence based histology analysis for onchocerciasis. The article also highlights our ongoing research and the need for novel animal models and new drug targets., Competing Interests: Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
- Published
- 2023
- Full Text
- View/download PDF
37. Increased HIV Incidence in Wuchereria bancrofti Microfilaria Positive Individuals in Tanzania.
- Author
-
Mnkai J, Ritter M, Maganga L, Maboko L, Olomi W, Clowes P, Minich J, Lelo AE, Kariuki D, Debrah AY, Geldmacher C, Hoelscher M, Saathoff E, Chachage M, Pfarr K, Hoerauf A, and Kroidl I
- Abstract
Background: Infections with Wuchereria bancrofti are associated with reduced immunity against concomitant infections. Indeed, our previous study described a 2.3-fold increased HIV incidence among individuals with W. bancrofti infection, as measured by the circulating filarial antigen of the adult worm. This new study aimed to retrospectively determine microfilariae status of the participants to assess if the previously described increased HIV susceptibility was associated with the presence of MF in the same cohort., Methods: CFA positive but HIV negative biobanked human blood samples ( n = 350) were analyzed for W. bancrofti MF chitinase using real time PCR., Results: The PCR provided a positive signal in 12/350 (3.4%) samples. During four years of follow-up (1109 person years (PY)), 22 study participants acquired an HIV infection. In 39 PY of W. bancrofti MF chitinase positive individuals, three new HIV infections occurred (7.8 cases per 100 PY), in contrast to 19 seroconversions in 1070 PY of W. bancrofti MF chitinase negative individuals (1.8 cases per 100 PY, p = 0.014)., Conclusions: In the subgroup of MF-producing Wb-infected individuals, the HIV incidence exceeded the previously described moderate increased risk for HIV seen in all Wb-infected individuals (regardless of MF status) compared with uninfected persons from the same area.
- Published
- 2023
- Full Text
- View/download PDF
38. Application of loop mediated isothermal amplification (LAMP) assays for the detection of Onchocerca volvulus , Loa loa and Mansonella perstans in humans and vectors.
- Author
-
Amambo GN, Innocentia N, Abong RA, Fombad FF, Njouendou AJ, Nietcho F, Ekanya R, Kien CA, Ebai R, Lenz B, Ritter M, Esum ME, Deribe K, Cho JF, Beng AA, Enyong PI, Li Z, Hübner MP, Pfarr K, Hoerauf A, Carlow C, and Wanji S
- Abstract
Conventional diagnosis of filarial infections is based on morphological identification of microfilariae using light microscopy and requires considerable expertise, is time-consuming, and can be subjective. Loop-mediated isothermal amplification (LAMP) has advantages over microscopy or PCR because of its operational simplicity, rapidity and versatility of readout options. LAMP assays represent a major step forward in improved filarial diagnostic tools suitable for low resource settings and field applicability. The study goal was to retrospectively evaluate the performance and suitability of the O-150, RF4, and Mp419 LAMP assays for diagnosing Onchocerca volvulus , Loa loa and Mansonella perstans infections, respectively, in humans and vectors under experimental and natural field conditions. Surveys were conducted in four health districts of Cameroon using skin snip and thick blood film methods to detect skin ( O. volvulus ) and blood ( L. loa and M. perstans ) dwelling microfilaria in humans. Engorged vectors ( Simulium spp ., Chrysops spp ., and Culicoides spp.) were evaluated by LAMP. Dissected, wild-caught vectors were also analyzed. LAMP showed a prevalence of 40.4% ( O. volvulus ), 17.8% ( L. loa ) and 36.6% ( M. perstans ) versus 20.6% ( O. volvulus ), 17.4% ( L. loa ) and 33.8% ( M. perstans ) with microscopy. Simulium spp. were dissected for microscopy and pooled for LAMP. The O-150 LAMP assay infection rate was 4.3% versus 4.1% by microscopy. Chrysops spp. were dissected and analyzed individually in the LAMP assay. The RF4 LAMP assay infection rate was 23.5% versus 3.3% with microscopy. The RF4 LAMP assay also detected parasites in Chrysops spp. fed on low microfilaremic volunteers. The Mp419 LAMP assay infection rate was 0.2% for C. milnei and 0.04% for C. grahamii , while three other species were LAMP-negative. The sensitivity, species specificity, rapidity and ease of its use of these filarial LAMP assays, and validation of their performance in the field support use as alternatives to microscopy as diagnostic and surveillance tools in global health programs aimed to eliminate onchocerciasis., Competing Interests: Conflict of interest ZL and CC are employees of New England Biolabs, manufacturer of LAMP reagents described in the manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
39. Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus .
- Author
-
Rox K, Becker T, Schiefer A, Grosse M, Ehrens A, Jansen R, Aden T, Kehraus S, König GM, Krome AK, Hübner MP, Wagner KG, Stadler M, Pfarr K, and Hoerauf A
- Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a World Health Organization’s high priority pathogen organism, with an estimated > 100,000 deaths worldwide in 2019. Thus, there is an unmet medical need for novel and resistance-breaking anti-infectives. The natural product Co-rallopyronin A (CorA), currently in preclinical development for filariasis, is efficacious against MRSA in vitro. In this study, we evaluated the pharmacokinetics of CorA after dosing in mice. Furthermore, we determined compound concentrations in target compartments, such as lung, kidney and thigh tissue, using LC-MS/MS. Based on the pharmacokinetic results, we evaluated the pharmacodynamic profile of CorA using the standard neutropenic thigh and lung infection models. We demonstrate that CorA is effective in both standard pharmacodynamic models. In addition to reaching effective levels in the lung and muscle, CorA was detected at high levels in the thigh bone. The data presented herein encourage the further exploration of the additional CorA indications treatment of MRSA- and methicillin-sensitive S. aureus- (MSSA) related infections.
- Published
- 2022
- Full Text
- View/download PDF
40. Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children.
- Author
-
Al-Obaidi I, Krome AK, Wagner KG, Pfarr K, Kuesel AC, and Batchelor HK
- Subjects
- Child, Humans, Child, Preschool, Neglected Diseases drug therapy, Drug Compounding, HIV Infections drug therapy, Tropical Medicine
- Abstract
It is recognised that paediatric indications and age-appropriate formulations are required to ensure that paediatric populations receive appropriate pharmacotherapeutic treatment. The lack of information on dosing, efficacy and safety data (labelling) is a well-recognised problem for all diseases affecting children. For neglected tropical diseases, the fact that they affect to a large extent poor and marginalised populations in low- and middle-income countries means that there is a low economic return on investment into paediatric development activities compared to other diseases [e.g. human immunodeficiency virus (HIV)]. This review provides an introduction to issues affecting the availability and development of paediatric population-relevant data and appropriate formulations of drugs for NTDs. We are summarising why age-appropriate formulations are important to ensure treatment efficacy, safety and effectiveness, outline initiatives to increase the number of paediatric indications/labelling and age-appropriate formulations, provide an overview of publicly available information on the formulations of oral drugs for NTDs relative to age appropriateness and give an introduction to options for age-appropriate formulations. The review completes with 'case studies' of recently developed paediatric formulations for NTDs, complemented by case studies for fixed-dose combinations for HIV infection in children since such formulations have not been developed for NTDs., (© 2022. World Health Organization.)
- Published
- 2022
- Full Text
- View/download PDF
41. Identification of the onchocerciasis vector in the Kakoi-Koda focus of the Democratic Republic of Congo.
- Author
-
Post RJ, Laudisoit A, Mandro M, Lakwo T, Laemmer C, Pfarr K, Hoerauf A, Tortosa P, Gomard Y, Ukety T, Mande C, Farovitch L, Amazigo U, Bakajika D, Oguttu DW, Awaca N, and Colebunders R
- Subjects
- Adult, Animals, Female, Humans, Democratic Republic of the Congo epidemiology, Insect Vectors, Plant Breeding, Onchocerciasis epidemiology, Onchocerca volvulus, Simuliidae genetics
- Abstract
Background: The objective of this study was to characterise the vector in a small hyper-endemic focus of onchocerciasis (the Kakoi-Koda focus) which has recently been discovered on the western slopes of the rift valley above Lake Albert., Methodology/principal Findings: Aquatic stages of blackflies were collected by hand from streams and rivers, and anthropophilic adult females were collected by human landing catches. Using a combination of morphotaxonomy and DNA barcoding, the blackflies collected biting humans within the focus were identified as Simulium dentulosum and Simulium vorax, which were also found breeding in local streams and rivers. Simulium damnosum s.l., Simulium neavei and Simulium albivirgulatum were not found (except for a single site in 2009 where crabs were carrying S. neavei). Anthropophilic specimens from the focus were screened for Onchocerca DNA using discriminant qualitative real-time triplex PCR. One specimen of S. vorax was positive for Onchocerca volvulus in the body, and out of 155 S. dentulosum, 30% and 11% were infected and infective (respectively)., Conclusions/significance: Simulium dentulosum currently appears to be the main vector of human onchocerciasis within the Kakoi-Koda focus, and S. vorax may be a secondary vector. It remains possible that S. neavei was the main (or only) vector in the past having now become rare as a result of the removal of tree-cover and land-use changes. Simulium vorax has previously been shown to support the development of O. volvulus in the laboratory, but this is the first time that S. dentulosum has been implicated as a probable vector of onchocerciasis, and this raises the possibility that other blackfly species which are not generally considered to be anthropophilic vectors might become vectors under suitable conditions. Because S. dentulosum is not a vector in endemic areas surrounding the Kakoi-Koda focus, it is probable that the Kakoi-Koda focus is significantly isolated., Competing Interests: No authors have competing interests., (Copyright: © 2022 Post et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2022
- Full Text
- View/download PDF
42. Potent In Vitro and Ex Vivo Anti-Gonococcal Activity of the RpoB Inhibitor Corallopyronin A.
- Author
-
Edwards JL, Balthazar JT, Esposito DLA, Ayala JC, Schiefer A, Pfarr K, Hoerauf A, Alt S, Hesterkamp T, Grosse M, Stadler M, Golparian D, Unemo M, Read TD, and Shafer WM
- Subjects
- Humans, Neisseria gonorrhoeae genetics, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Chlamydia trachomatis, Gonorrhea drug therapy, Gonorrhea prevention & control, Coinfection, Anti-Infective Agents pharmacology
- Abstract
Gonorrhea remains a major global public health problem because of the high incidence of infection (estimated 82 million cases in 2020) and the emergence and spread of Neisseria gonorrhoeae strains resistant to previous and current antibiotics used to treat infections. Given the dearth of new antibiotics that are likely to enter clinical practice in the near future, there is concern that cases of untreatable gonorrhea might emerge. In response to this crisis, the World Health Organization (WHO), in partnership with the Global Antibiotic Research and Development Partnership (GARDP), has made the search for and development of new antibiotics against N. gonorrhoeae a priority. Ideally, these antibiotics should also be active against other sexually transmitted organisms, such as Chlamydia trachomatis and/or Mycoplasma genitalium, which are often found with N. gonorrhoeae as co-infections. Corallopyronin A is a potent antimicrobial that exhibits activity against Chlamydia spp. and inhibits transcription by binding to the RpoB switch region. Accordingly, we tested the effectiveness of corallopyronin A against N. gonorrhoeae. We also examined the mutation frequency and modes of potential resistance against corallopyronin A. We report that corallopyronin A has potent antimicrobial action against antibiotic-susceptible and antibiotic-resistant N. gonorrhoeae strains and could eradicate gonococcal infection of cultured, primary human cervical epithelial cells. Critically, we found that spontaneous corallopyronin A-resistant mutants of N. gonorrhoeae are exceedingly rare (≤10
-10 ) when selected at 4× the MIC. Our results support pre-clinical studies aimed at developing corallopyronin A for gonorrheal treatment regimens. IMPORTANCE The high global incidence of gonorrhea, the lack of a protective vaccine, and the emergence of N. gonorrhoeae strains expressing resistance to currently used antibiotics demand that new treatment options be developed. Accordingly, we investigated whether corallopyronin A, an antibiotic which is effective against other pathogens, including C. trachomatis, which together with gonococci frequently cause co-infections in humans, could exert anti-gonococcal action in vitro and ex vivo , and potential resistance emergence. We propose that corallopyronin A be considered a potential future treatment option for gonorrhea because of its potent activity, low resistance development, and recent advances in scalable production.- Published
- 2022
- Full Text
- View/download PDF
43. Corallopyronin A: antimicrobial discovery to preclinical development.
- Author
-
Krome AK, Becker T, Kehraus S, Schiefer A, Gütschow M, Chaverra-Muñoz L, Hüttel S, Jansen R, Stadler M, Ehrens A, Pogorevc D, Müller R, Hübner MP, Hesterkamp T, Pfarr K, Hoerauf A, Wagner KG, and König GM
- Subjects
- Anti-Bacterial Agents pharmacology, Humans, Lactones, Water, Anti-Infective Agents pharmacology, Biological Products pharmacology
- Abstract
Covering: August 1984 up to January 2022Worldwide, increasing morbidity and mortality due to antibiotic-resistant microbial infections has been observed. Therefore, better prevention and control of infectious diseases, as well as appropriate use of approved antibacterial drugs are crucial. There is also an urgent need for the continuous development and supply of novel antibiotics. Thus, identifying new antibiotics and their further development is once again a priority of natural product research. The antibiotic corallopyronin A was discovered in the 1980s in the culture broth of the Myxobacterium Corallococcus coralloides and serves, in the context of this review, as a show case for the development of a naturally occurring antibiotic compound. The review demonstrates how a hard to obtain, barely water soluble and unstable compound such as corallopyronin A can be developed making use of sophisticated production and formulation approaches. Corallopyronin A is a bacterial DNA-dependent RNA polymerase inhibitor with a new target site and one of the few representatives of this class currently in preclinical development. Efficacy against Gram-positive and Gram-negative pathogens, e.g. , Chlamydia trachomatis , Orientia tsutsugamushi , Staphylococcus aureus , and Wolbachia has been demonstrated. Due to its highly effective in vivo depletion of Wolbachia , which are essential endobacteria of most filarial nematode species, and its robust macrofilaricidal efficacy, corallopyronin A was selected as a preclinical candidate for the treatment of human filarial infections. This review highlights the discovery and production optimization approaches for corallopyronin A, as well as, recent preclinical efficacy results demonstrating a robust macrofilaricidal effect of the anti- Wolbachia candidate, and the solid formulation strategy which enhances the stability as well as the bioavailability of corallopyronin A.
- Published
- 2022
- Full Text
- View/download PDF
44. In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin A.
- Author
-
Becker T, Krome AK, Vahdati S, Schiefer A, Pfarr K, Ehrens A, Aden T, Grosse M, Jansen R, Alt S, Hesterkamp T, Stadler M, Hübner MP, Kehraus S, König GM, Hoerauf A, and Wagner KG
- Abstract
In vivo studies in mice provide a valuable model to test novel active pharmaceutical ingredients due to their low material need and the fact that mice are frequently used as a species for early efficacy models. However, preclinical in vitro evaluations of formulation principles in mice are still lacking. The development of novel in vitro and in silico models supported the preclinical formulation evaluation for the anti-infective corallopyronin A (CorA). To this end, CorA and solubility-enhanced amorphous solid dispersion formulations, comprising povidone or copovidone, were evaluated regarding biorelevant solubilities and dissolution in mouse-specific media. As an acidic compound, CorA and CorA-ASD formulations showed decreased solubilities in mice when compared with human-specific media. In biorelevant biphasic dissolution experiments CorA-povidone showed a three-fold higher fraction partitioned into the organic phase of the biphasic dissolution, when compared with CorA-copovidone. Bioavailabilities determined by pharmacokinetic studies in BALB/c mice correlated with the biphasic dissolution prediction and resulted in a Level C in vitro-in vivo correlation. In vitro cell experiments excluded intestinal efflux by P-glycoprotein or breast cancer resistance protein. By incorporating in vitro results into a physiologically based pharmacokinetic model, the plasma concentrations of CorA-ASD formulations were predicted and identified dissolution as the limiting factor for bioavailability.
- Published
- 2022
- Full Text
- View/download PDF
45. The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus .
- Author
-
Balansky J, Pfarr K, Szekat C, Kehraus S, Aden T, Grosse M, Jansen R, Hesterkamp T, Schiefer A, König GM, Stadler M, Hoerauf A, and Bierbaum G
- Abstract
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S. aureus using fluctuation analysis at 4 × minimum inhibitory concentration (MIC). Resistant mutants were characterized. S. aureus strains HG001, Mu50, N315, and USA300 had an MIC of 0.25 mg/L. The median FoM for CorA resistance was 1.5 × 10−8, 4.5-fold lower than the median FoM of 6.7 × 10−8 for rifampicin, and was reflected in a 4-fold lower mutation rate for CorA than rifampicin (6 × 10−9 for CorA vs. 2.5 × 10−8 for rifampicin). In CorA-resistant/rifampicin-sensitive strains, the majority of amino acid exchanges were S1127L in RpoB or K334N in RpoC. S. aureus Mu50, a rifampicin-resistant clinical isolate, yielded two further exchanges targeting amino acids L1131 and E1048 of the RpoB subunit. The plating of >1011 cells on agar containing a combination of 4 × MIC of rifampicin and 4 × MIC of CorA did not yield any growth. In conclusion, with proper usage, e.g., in combination therapy and good antibiotic stewardship, CorA is a potential antibiotic for treating S. aureus infections.
- Published
- 2022
- Full Text
- View/download PDF
46. A qPCR to quantify Wolbachia from few Onchocerca volvulus microfilariae as a surrogate for adult worm histology in clinical trials of antiwolbachial drugs.
- Author
-
Schlabe S, Korir P, Lämmer C, Landmann F, Dubben B, Koschel M, Albers A, Debrah LB, Debrah AY, Hübner MP, Pfarr K, Klarmann-Schulz U, and Hoerauf A
- Subjects
- Animals, Humans, Microfilariae, Onchocerca, Reproducibility of Results, Filarioidea, Onchocerca volvulus genetics, Wolbachia drug effects, Wolbachia genetics
- Abstract
The filarial nematode Onchocerca volvulus causes onchocerciasis (river blindness), a neglected tropical disease affecting 21 million people, mostly in Sub-Saharan Africa. Targeting the endosymbiont Wolbachia with antibiotics leads to permanent sterilization and killing of adult worms. The gold standard to assess Wolbachia depletion is the histological examination of adult worms in nodules beginning at 6 months post-treatment. However, nodules can only be used once, limiting the time points to monitor Wolbachia depletion. A diagnostic to longitudinally monitor Wolbachia depletion from microfilariae (MF) at more frequent intervals < 6 months post-treatment would accelerate clinical trials of antiwolbachials. We developed a TaqMan qPCR amplifying the single-copy gene wOvftsZ to quantify Wolbachia from as few as one MF that had migrated from skin biopsies and compared quantification using circular and linearized plasmids or synthetic dsDNA (gBlock®). qPCR for MF from the rodent nematode Litomosoides sigmodontis was used to support the reproducibility and validate the principle. The qPCR using as few as 2 MF from O. volvulus and L. sigmodontis reproducibly quantified Wolbachia. Use of a linearized plasmid standard or synthesized dsDNA resulted in numbers of Wolbachia/MF congruent with biologically plausible estimates in O. volvulus and L. sigmodontis MF. The qPCR assay yielded a median of 48.8 (range 1.5-280.5) Wolbachia/O. volvulus MF. The qPCR is a sensitive tool for quantifying Wolbachia in a few MF from skin biopsies and allows for establishing the qPCR as a surrogate parameter for monitoring Wolbachia depletion in adult worms of new antiwolbachial candidates., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
47. Onchocerca volvulus transmission in the Mbam valley of Cameroon following 16 years of annual community-directed treatment with ivermectin, and the description of a new cytotype of Simulium squamosum.
- Author
-
Hendy A, Krit M, Pfarr K, Laemmer C, De Witte J, Nwane P, Kamgno J, Nana-Djeunga HC, Boussinesq M, Dujardin JC, Post R, Colebunders R, O'Neill S, Enyong P, and Njamnshi AK
- Subjects
- Animals, Cameroon epidemiology, Female, Humans, Insect Control, Insect Vectors genetics, Insect Vectors parasitology, Insect Vectors physiology, Male, Onchocerca volvulus genetics, Onchocerca volvulus physiology, Onchocerciasis epidemiology, Onchocerciasis parasitology, Rural Health, Seasons, Simuliidae genetics, Simuliidae parasitology, Simuliidae physiology, Insect Vectors drug effects, Insecticides pharmacology, Ivermectin pharmacology, Onchocerca volvulus drug effects, Onchocerciasis transmission, Simuliidae drug effects
- Abstract
Background: The onchocerciasis focus surrounding the lower Mbam and Sanaga rivers, where Onchocerca volvulus is transmitted by Simulium damnosum s.l. (Diptera: Simuliidae), was historically the largest in the southern regions of Cameroon. Annual community-directed treatment with ivermectin (CDTI) has been taking place since 2000, but recent studies have shown that new infections are occurring in children. We aimed to investigate blackfly biting and O. volvulus transmission rates along the lower Mbam river 16 years after the formal onset of annual CDTI., Methods: Black flies were collected for three consecutive days each month between July 2016 and June 2017 at two riverside villages and two inland sites situated 4.9 km and 7.9 km from the riverside. Specimens collected at each site were dissected on one of the three collection days each month to estimate parity rates and O. volvulus infection rates, while the remaining samples were preserved for pool screening., Results: In total, 93,573 S. damnosum s.l. black flies were recorded biting humans and 9281 were dissected. Annual biting rates of up to 606,370 were estimated at the riverside, decreasing to 20,540 at 7.9 km, while, based on dissections, annual transmission potentials of up to 4488 were estimated at the riverside, decreasing to 102 and 0 at 4.9 km and 7.9 km, respectively. However, pool screening showed evidence of infection in black flies at the furthest distance from the river. Results of both methods demonstrated the percentage of infective flies to be relatively low (0.10-0.36%), but above the WHO threshold for interruption of transmission. In addition, a small number of larvae collected during the dry season revealed the presence of Simulium squamosum E. This is the first time S. squamosum E has been found east of Lake Volta in Ghana, but our material was chromosomally distinctive, and we call it S. squamosum E2., Conclusions: Relatively low O. volvulus infection rates appear to be offset by extremely high densities of biting black flies which are sustaining transmission along the banks of the lower Mbam river., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
48. Towards the sustainable discovery and development of new antibiotics.
- Author
-
Miethke M, Pieroni M, Weber T, Brönstrup M, Hammann P, Halby L, Arimondo PB, Glaser P, Aigle B, Bode HB, Moreira R, Li Y, Luzhetskyy A, Medema MH, Pernodet JL, Stadler M, Tormo JR, Genilloud O, Truman AW, Weissman KJ, Takano E, Sabatini S, Stegmann E, Brötz-Oesterhelt H, Wohlleben W, Seemann M, Empting M, Hirsch AKH, Loretz B, Lehr CM, Titz A, Herrmann J, Jaeger T, Alt S, Hesterkamp T, Winterhalter M, Schiefer A, Pfarr K, Hoerauf A, Graz H, Graz M, Lindvall M, Ramurthy S, Karlén A, van Dongen M, Petkovic H, Keller A, Peyrane F, Donadio S, Fraisse L, Piddock LJV, Gilbert IH, Moser HE, and Müller R
- Abstract
An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations., (© 2021. Springer Nature Limited.)
- Published
- 2021
- Full Text
- View/download PDF
49. Urine metabolites for the identification of Onchocerca volvulus infections in patients from Cameroon.
- Author
-
Wewer V, Peisker H, Gutbrod K, Al-Bahra M, Menche D, Amambo NG, Fombad FF, Njouendou AJ, Pfarr K, Wanji S, Hoerauf A, and Dörmann P
- Subjects
- Animals, Biomarkers urine, Cameroon epidemiology, Chromatography, Liquid methods, Glucuronides urine, Glycine analogs & derivatives, Glycine urine, Humans, Mass Spectrometry methods, Onchocerciasis epidemiology, Onchocerciasis, Ocular diagnosis, Onchocerciasis, Ocular urine, Metabolome, Onchocerca volvulus pathogenicity, Onchocerciasis diagnosis, Onchocerciasis urine
- Abstract
Background: The tropical disease onchocerciasis (river blindness), caused by Onchocerca volvulus filarial nematodes, is targeted for elimination by mass treatment with nematocidal and antimicrobial drugs. Diagnosis of O. volvulus infections is based on counts of skin-borne microfilariae, but additional diagnostic tools, e.g. worm- or host-derived small RNAs, proteins or metabolites, are required for high-throughput screening. N-acetyltyramine-O,β-glucuronide (NATOG) was suggested as a biomarker for onchocerciasis but its viability as diagnostic tool has been challenged., Methods: We performed a screening program of urine samples from individuals from Cameroon infected with O. volvulus, Loa loa, Mansonella perstans or a combination thereof. Urine metabolites were measured by liquid chromatography-mass spectrometry (LC-MS). Principle component analysis (PCA) revealed that onchocerciasis causes complex changes of the urine metabolome., Results: The mean NATOG content was elevated in urine of O. volvulus-infected compared with non-infected individuals, but NATOG levels showed considerable variation. However, 13.8% of all O. volvulus-infected individuals had high NATOG levels never reached by individuals without filarial infections or only infected with L. loa or M. perstans. Therefore, the identification of individuals with high NATOG levels might be used to screen for the elimination of onchocerciasis after mass drug application. Additional metabolites, including a compound identified as cinnamoylglycine, had high PC1/PC2 loadings in the data set. Mean levels of cinnamoylglycine were increased in O. volvulus-infected individuals, and 17.2% of all O. volvulus individuals had elevated cinnamoylglycine levels not reached by the controls., Conclusions: On an individual level, NATOG alone had poor discriminative power distinguishing infected from non-infected individuals. However, 13.8% of all O. volvulus-infected individuals had NATOG levels never reached by individuals without filarial infections or infected with only L. loa or M. perstans. Discrimination of O. volvulus infections from controls or individuals suffering from multiple infections was improved by the measurement of additional metabolites, e.g. cinnamoylglycine. Thus, measuring a combination of urine metabolites may provide a way to assess onchocerciasis on the population level. This provides the possibility to design a strategy for large-scale onchocerciasis epidemiological screening programs based on urine rather than invasive techniques., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
50. The Mbam drainage system and onchocerciasis transmission post ivermectin mass drug administration (MDA) campaign, Cameroon.
- Author
-
Abong RA, Amambo GN, Hamid AA, Enow BA, Beng AA, Nietcho FN, Nji TM, Njouendou AJ, Ritter M, Esum ME, Deribe K, Cho JF, Fombad FF, Enyong PI, Poole C, Pfarr K, Hoerauf A, Carlow C, and Wanji S
- Subjects
- Animals, Antiparasitic Agents therapeutic use, Cameroon epidemiology, Female, Humans, Insect Bites and Stings epidemiology, Insect Vectors parasitology, Ivermectin therapeutic use, Lysosomal-Associated Membrane Protein 3, Mass Drug Administration, Onchocerca classification, Onchocerca genetics, Onchocerciasis diagnosis, Real-Time Polymerase Chain Reaction, Rivers, Seasons, Simuliidae physiology, Onchocerca isolation & purification, Onchocerciasis prevention & control, Onchocerciasis transmission, Simuliidae parasitology
- Abstract
Background: The impact of large scale Mass Drug Adminstration (MDA) of ivermectin on active onchocerciasis transmission by Simulium damnosum, which transmits the parasite O. volvulus is of great importance for onchocerciasis control programmes. We investigated in the Mbam river system area, the impact of MDA of ivermectin on entomological indices and also verify if there are river system factors that could have favoured the transmission of onchocerciasis in this area and contribute to the persistence of disease. We compared three independent techniques to detect Onchocerca larvae in blackflies and also analyzed the river system within 9 months post-MDA of ivermectin., Method: Simulium flies were captured before and after 1, 3, 6 and 9months of ivermectin-MDA. The biting rate was determined and 41% of the flies dissected while the rest were grouped into pools of 100 flies for DNA extraction. The extracted DNA was then subjected to O-150 LAMP and real-time PCR for the detection of infection by Onchocerca species using pool screening. The river system was analysed and the water discharge compared between rainy and dry seasons., Principal Findings: We used human landing collection method (previously called human bait) to collect 22,274 adult female Simulium flies from Mbam River System. Of this number, 9,134 were dissected while 129 pools constituted for molecular screening. Overall biting and parous rates of 1113 flies/man/day and 24.7%, respectively, were observed. All diagnostic techniques detected similar rates of O. volvulus infection (P = 0.9252) and infectivity (P = 0.4825) at all monitoring time points. Onchocerca ochengi larvae were only detected in 2 of the 129 pools. Analysis of the river drainage revealed two hydroelectric dams constructed on the tributaries of the Mbam river were the key contributing factor to the high-water discharge during both rainy and dry seasons., Conclusion: Results from fly dissection (Microscopy), real-time PCR and LAMP revealed the same trends pre- and post-MDA. The infection rate with animal Onchocerca sp was exceptionally low. The dense river system generate important breeding sites that govern the abundance of Simulium during both dry and rainy seasons., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.